Low Dose DCB Showed No Statistically Significant Difference in Patency versus Higher Dose DCB
Learn about the world’s first head-to-head prospective, randomized (1:1) controlled trial comparing the lower dose paclitaxel Ranger DCB (2 μg/mm2) to the higher dose paclitaxel IN.PACT DCB (3.5 μg/mm2).
Perspectives on COMPARE-1
All Resources (-)
PDF( 351.0 KB )
Protocol pre-specified interim analysis of first 150 patients (COMPARE pilot) after 12-months of follow-up presented at LINC 2018*
*Results from the 150 patients from the pilot phase. Overall trial will enroll up to 414 patients.